| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
1 Department of Urology, College of Physicians and Surgeons and 2 Department of Biostatistics, School of Public Health, Columbia University Medical Center, New York, New York
Purpose: Isoflavones have anticancer activities, but naturally occurring isoflavones are predominantly glycosylated and poorly absorbed. Genistein combined polysaccharide (GCP; Amino Up Chemical Co., Sapporo, Japan), is a fermentation product of soy extract and basidiomycetes mycillae that is enriched in biologically active aglycone isoflavones. This study analyzes GCP in vitro and in vivo for potential utility as a prostate cancer chemopreventative agent.
Experimental Design: Androgen-sensitive LNCaP and androgen-independent PC-3 cells were grown with various concentrations of GCP. In vitro cell growth was analyzed by the WST-1 assay, and apoptosis was assessed by fluorescence-activated cell sorting and detection of poly(ADP-ribose) polymerase cleavage using Western blot techniques. Effects of GCP on expression of cell cycle-regulatory proteins p53 (LNCaP only), p21, and p27 and the protein kinase Akt were considered using Western blot techniques. An in vivo LNCaP xenograft model was used to study the effects of a 2% GCP-supplemented diet on tumor growth in comparison with a control diet.
Results: GCP significantly suppressed LNCaP and PC-3 cell growth over 72 h (89% and 78% in LNCaP and PC-3, respectively, at 10 µg/ml; P < 0.0001). This reduction was associated with apoptosis in LNCaP cells, but not in PC-3 cells. GCP induced p27 and p53 (LNCaP only) protein expression within 6 h and suppressed phosphorylated Akt in both cell lines. The 2% GCP-supplemented diet significantly slowed LNCaP tumor growth, increasing apoptosis (P < 0.001), and decreasing proliferation (P < 0.001) over 4 weeks.
Conclusions: GCP has potent growth-inhibitory effects against prostate cancer cell lines in vitro and in vivo. These data suggest GCP has potential as an effective chemopreventive agent against prostate cancer cell growth.
This article has been cited by other articles:
|
|
 |
|
  L. Yan and E. L Spitznagel Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis Am. J. Clinical Nutrition, April 1, 2009; 89(4): 1155 - 1163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Jamadar-Shroff, M. G. Papich, and S. E. Suter Soy-Derived Isoflavones Inhibit the Growth of Canine Lymphoid Cell Lines Clin. Cancer Res., February 15, 2009; 15(4): 1269 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Vinall, K. Hwa, P. Ghosh, C.-X. Pan, P. N. Lara Jr., and R. W. de Vere White Combination Treatment of Prostate Cancer Cell Lines with Bioactive Soy Isoflavones and Perifosine Causes Increased Growth Arrest and/or Apoptosis Clin. Cancer Res., October 15, 2007; 13(20): 6204 - 6216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-H. Chen, J. Fang, H. Li, W. Demark-Wahnefried, and X. Lin Enterolactone induces apoptosis in human prostate carcinoma LNCaP cells via a mitochondrial-mediated, caspase-dependent pathway Mol. Cancer Ther., September 1, 2007; 6(9): 2581 - 2590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Akbas, X. Fei, and H. S. Taylor Regulation of HOXA10 expression by phytoestrogens Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E435 - E442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Lamb and L. Zhang Challenges in Prostate Cancer Research: Animal Models for Nutritional Studies of Chemoprevention and Disease Progression J. Nutr., December 1, 2005; 135(12): 3009S - 3015S. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
